Effect of long-term aluminum feeding on kinetics attributes of tissue cholinesterases.
Aluminum (Al) is considered a potential etiological factor in Alzheimer's disease (AD). Neurotoxicity from excess brain exposure to Al is documented from both clinical observations and animal experiments. A key role of the acetylcholine system in memory disturbances that characterize AD has been reported. On this basis, we studied the effect of long-term Al feeding on kinetic properties of cholinesterases employing the rat as experimental model. Animals were given prolonged treatment with soluble salts of Al (100mg AlCl(3)/kg body weight mixed with food for 100-115 days), and the kinetic properties of cholinesterases (acetylcholinesterase, AChE, and butyrylcholinesterase, BChE) were determined in different tissues. Prolonged treatment with Al had no effect on the K(m) values of the soluble and membrane-bound forms of AChE in the brain, but V(max) was instead decreased in all the components of soluble and membrane-bound forms of AChE in the brain. In addition, the Al treatment resulted in complete loss of the component II of erythrocyte membrane AChE. Surprisingly, after prolonged treatment with Al, higher V(max) was observed in all the components of soluble and membrane-bound forms of BChE in the heart and liver. Variable effects of Al exposure were observed on temperature kinetic properties of cholinesterases. Altogether these findings indicate that long-term Al feeding results in inhibition of AChE, while an opposite effect is observed on BChE. Decreased V(max) of the brain AChE could represent the mode of action through which Al may contribute to pathological processes in Al-induced neurotoxicity.
Dave
Kunjan R
KR
Department of Biochemistry, Faculty of Science, M.S. University of Baroda, Vadodara, India. krdave@stroke.med.miami.edu
Syal
Anshu R
AR
Katyare
Surendra S
SS
D000109:Acetylcholine / Q000378:metabolism*; D000110:Acetylcholinesterase / Q000097:blood / Q000187:drug effects; D017607:Aluminum Compounds / Q000633:toxicity*; D000544:Alzheimer Disease / Q000139:chemically induced* / Q000201:enzymology / Q000503:physiopathology; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology; D002091:Butyrylcholinesterase / Q000097:blood / Q000187:drug effects; D002462:Cell Membrane / Q000187:drug effects / Q000201:enzymology; D002802:Cholinesterases / Q000097:blood / Q000187:drug effects*; D004334:Drug Administration Schedule; D004912:Erythrocytes / Q000187:drug effects / Q000201:enzymology; D005526:Food, Formulated / Q000009:adverse effects*; D006321:Heart / Q000187:drug effects / Q000502:physiology; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009498:Neurotoxins / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains
D017607:Aluminum Compounds; D009498:Neurotoxins; D000110:Acetylcholinesterase; D002091:Butyrylcholinesterase; D002802:Cholinesterases; D000109:Acetylcholine